Table I. Patient characteristics at baseline (N=236).
CT: Computed tomography; ECOG: Eastern Cooperative Oncology Group; MRI: magnetic resonance imaging; PSA: prostate specific antigen; *D’Amico risk categories: Low-risk: Gleason score <6, PSA <10 ng/ml and clinical stage T1c or T2a; intermediate-risk: Gleason score 7 or PSA 10-20 ng/ml or clinical stage T2b; high risk: Gleason score 8-10 or PSA >20 ng/ml or clinical stage T2c, T3, T4.
